Developing a screening assay using dysferlin deficient cells
Objective: To develop a cell-based high throughput screening assay using dysferlin deficient cells
Project Summary: The aim of this project is to develop a simple test for the well-being of a muscle cell in the absence of dysferlin so that compounds that improve the well-being of dysferlin deficient muscle cells can be identified. The Jain Foundation has selected two different contract research organizations to develop this kind of cell-based, high throughput screening assay: BioFocus and Evotec. BioFocus and Evotec will each use different methods to assess specific cellular pathways identified by research scientists as being affected by dysferlin deficiency. It is our hope that at least one of the companies will succeed in developing a robust assay, and if both companies are successful, the results from either assay will be used to validate the results of the other.
About BioFocus: BioFocus offers comprehensive target to candidate drug discovery services, backed by centralized project management. BioFocus’ headquarters are in Saffron Walden (near Cambridge), UK, with facilities in The Netherlands and Switzerland, and sales offices in Japan, Singapore and the US. BioFocus employ 200 staff offering a range of products and services to biotech, pharma as well as patient and non-profit organizations. BioFocus is a service division of Galapagos NV. Galapagos’ drug discovery division develops novel and disease-modifying drugs in a number of therapeutic areas for which there is a need for better medicines.